BAY HARBOR ISLAND, Fla. (AP) — BAY HARBOR ISLAND, Fla. (AP) — Fortress Biotech Inc. (FBIO) on Thursday reported a loss of $10.6 million in its first quarter. On a per-share basis, the Bay ...

Our free stock report includes 4 warning signs investors should be aware of before investing in Fortress Biotech. Read for free now. Revenue exceeded analyst estimates by 13%. Earnings per share ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...

This includes 400 hours of hands-on biotech and life sciences training, mentorship, free on-campus housing, and a stipend. Each student will be matched with three mentors: a faculty member, an ...

LONDON (Reuters) -Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs ...

Hong Kong-based venture capital firm ORI Capital plans to launch a new fund to invest in Chinese healthcare start-ups, as the domestic biotechnology industry experiences its own “DeepSeek moment ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered ...

Some US biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs watchdog under the Trump ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. Biotech stocks lagged the broader market ...